BMO Capital Keeps a Hold Rating on Valeant Pharm International (VRX)


According to The Fly, a Wall Street analyst has provided a rating update for the Healthcare company on November 11, while remaining neutral on the stock. Valeant Pharm International (VRX) received a Hold on November 11 from BMO Capital’s analyst Gary Nachman.

According to TipRanks.com, Nachman is a 4-star analyst with an average return of 6.8% and a 50.8% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Sienna Biopharmaceuticals Inc, Bausch Health Companies Inc, and Aquestive Therapeutics Inc.

Read also: AcelRx (ACRX) Tumbles After Stock Offering Prices at Deep Discount

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Valeant Pharm International.

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts